BioInvent: Comment on the KOL Event on BI-1808 in Ovarian Cancer - Redeye

BioInvent hosted a virtual KOL event yesterday focusing on BI-1808 in advanced ovarian cancer. Guest speaker Dr Dmitriy Zamarin (Mount Sinai) highlighted the severe unmet need in recurrent ovarian cancer. The updated Phase IIa data for BI-1808 combined with Keytruda significantly outperformed historical benchmarks, showing a 24% ORR and an impressive preliminary median PFS of 10.3 months. We view these results as a strong validation of BioInvent’s TNFR2-targeting strategy.

Länk till analysen i sin helhet: https://www.redeye.se/research/1169944/bioinvent-comment-on-the-kol-event-on-bi-1808-in-ovarian-cancer?utm_source=finwire&utm_medium=RSS